◼ Archived
Business
🔮 fades ✗
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
The FDA has granted accelerated approval to Bristol Myers Squibb's Zenbexus, introducing a novel CELMoD drug class for multiple myeloma treatment.